Briacell announces rescheduling of its annual general meeting of shareholders to february 5, 2025

Philadelphia and vancouver, british columbia, jan. 03, 2025 (globe newswire) -- briacell therapeutics corp. (nasdaq: bctx, bctxw) (tsx: bct) (“briacell” or the “company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the company's annual general meeting of shareholders (the “meeting”), which was originally scheduled to be held on thursday, january 23, 2025, has been rescheduled. the meeting is now scheduled to be held on wednesday, february 5, 2025, at 9:00 a.m. (et) at suite 3400, one first canadian place, toronto, on, m5x 1a4. the record date for the meeting, december 9, 2024, is unchanged and applies to the postponed meeting. the meeting has been postponed due to delays stemming from the disruption in postal service in canada, and to provide further time to solicit proxies from the company's shareholders.
GM Ratings Summary
GM Quant Ranking